TerminatedPhase 2

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Stopped: The study was terminated early based on the results of a planned interim analysis.

United States90 participantsStarted 2015-11-18

Plain-language summary

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of AA * Duration and extent of current episode of AA * Evidence of active hair loss Exclusion Criteria: * Evidence of diffuse, spontaneous terminal hair regrowth * Receipt of treatment known to potentially affect the course of AA within last month

What they're measuring

Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).

Timeframe: Up to Week 24

Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)

Timeframe: Week 24

Trial details

NCT IDNCT02553330

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-10-03

Results submitted2020-10-02

View on ClinicalTrials.gov More Alopecia Areata trials